A share price of Moderna Inc [MRNA] is currently trading at $35.21, up 15.94%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MRNA shares have gain 4.85% over the last week, with a monthly amount drifted -3.67%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on February 18, 2025, when Barclays downgraded its rating to a Equal Weight and also revised its price target to $45 from $111. Previously, Goldman downgraded its rating to Neutral on January 29, 2025, and dropped its price target to $51. On December 18, 2024, downgrade downgraded it’s rating to Hold. Berenberg initiated its recommendation with a Hold and recommended $42 as its price target on November 19, 2024. HSBC Securities upgraded its rating to Buy for this stock on November 18, 2024, but kept the price target unchanged to $58. In a note dated November 15, 2024, Wolfe Research initiated an Underperform rating and provided a target price of $40 on this stock.
Moderna Inc experienced fluctuations in its stock price throughout the past year between $29.25 and $170.47. Currently, Wall Street analysts expect the stock to reach $82.11 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $35.21 at the most recent close of the market. An investor can expect a potential return of 133.2% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
Trailing Twelve Months sales for Moderna Inc [NASDAQ:MRNA] were 3.24B which represents -65.54% decline. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -1.22%, Pretax Profit Margin comes in at -1.12%, and Net Profit Margin reading is -1.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.3 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.28 points at the first support level, and at 29.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.76, and for the 2nd resistance point, it is at 38.32.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Moderna Inc [NASDAQ:MRNA] is 3.67. Also, the Quick Ratio is 3.62, while the Cash Ratio stands at 0.87. Considering the valuation of this stock, the price to sales ratio is 4.20, the price to book ratio is 1.25.
Transactions by insiders
Recent insider trading involved Bancel Stephane, Chief Executive Officer, that happened on Mar 03 ’25 when 0.16 million shares were purchased. Director, SAGAN PAUL completed a deal on Mar 03 ’25 to buy 31620.0 shares. Meanwhile, Chief Legal Officer Klinger Shannon Thyme sold 529.0 shares on Dec 09 ’24.
